3B BlackBio Dx shareholders approve FY26 results and ₹5 dividend
- Consolidated profit after tax stood at ₹59.92 crore for FY26
- Final dividend of ₹5.00 per equity share recommended and approved
- UK subsidiary sales grew 36% YoY to £1.75 million
- Mithla Dubey re-appointed as director with 96.79% votes in favour
*this image is generated using AI for illustrative purposes only.
3B BlackBio Dx Limited reported a consolidated profit after tax of ₹59.92 crore for the financial year ended March 31, 2026, alongside revenue from operations of ₹141.91 crore. The board recommended a final dividend of ₹5.00 per equity share for the period.
The results include financials from Coris BioConcept, acquired on August 29, 2025, consolidated under Ind AS rules from the acquisition date. Earnings per share stood at ₹69.94, with profit before tax recorded at ₹76.96 crore. The company operates in the molecular diagnostics sector, with infectious disease assays contributing approximately 60% of sales and oncology assays accounting for 40%.
Export growth and UK subsidiary performance
Export sales rose to ₹21.41 crore in FY26 from ₹17.03 crore in FY25. The company noted that geopolitical tensions in the Middle East impacted some export orders, limiting potential growth. The export mix comprises approximately 45% from Europe, 25% from the Middle East, 25% from APAC, and 5% from the rest of the world.
The UK subsidiary, TRUPCR Europe Limited, achieved sales of £1.75 million in FY26, up from £1.28 million in FY25, representing a 36% year-on-year increase. Over the last four years, the subsidiary has recorded a CAGR of 57.20%.
| Fiscal Year | Sales (GBP) |
|---|---|
| FY 2022-23 | 451,195 |
| FY 2023-24 | 679,464 |
| FY 2024-25 | 1,287,580 |
| FY 2025-26 | 1,751,860 |
R&D intensity and market positioning
Research and development expenditure increased to 3.51% of revenue in FY26, up from 2.58% in FY25, reflecting a year-on-year growth of approximately 46%. The company holds a 12%–15% market share in India’s molecular diagnostics market, estimated at ₹500–600 crore. It aims for 15%–20% growth in FY27, supported by a portfolio of over 120 PCR assays.
AGM resolutions and shareholder approval
At the 54th Annual General Meeting held on September 29, 2026, shareholders voted on five resolutions via remote e-voting. All resolutions were passed with requisite majorities. The adoption of audited standalone and consolidated financial statements for FY26 received overwhelming support, with 100% of valid votes cast in favour for both items.
The declaration of a dividend of ₹5 per equity share (50% of face value) was also approved unanimously by voting members. Additionally, the remuneration of cost auditors Sanjay Kasliwal & Associates was ratified.
One notable divergence appeared in the re-appointment of director Mithla Dubey. While promoters voted entirely in favour, public non-institutional shareholders registered dissenting votes amounting to 3.21% of the total votes polled against this specific special resolution. Mrs. Mithla Dubey, aged 79 years, was re-appointed as she retires by rotation and offers herself for re-appointment as per the Articles of Association. She is the mother of Mr. Dhirendra Dubey, Chairman cum Managing Director, and Mr. Nikhil Kuber Dubey, Whole-Time Director cum CFO. Her appointment ensures compliance with SEBI regulations requiring at least one woman director on the board.
| Resolution Item | Votes In Favour (%) | Votes Against (%) | Status |
|---|---|---|---|
| Adopt Standalone Financials (FY26) | 100.00 | 0.00 | Passed |
| Adopt Consolidated Financials (FY26) | 99.99 | 0.01 | Passed |
| Declare Dividend (₹5 per share) | 100.00 | 0.00 | Passed |
| Re-appoint Director Mithla Dubey | 96.79 | 3.21 | Passed |
| Ratify Cost Auditor Remuneration | 100.00 | 0.00 | Passed |
What the Numbers Show
The correlation between rising R&D spend and robust export growth highlights a strategy focused on product differentiation. With R&D intensity increasing by nearly 100 basis points YoY, the company is investing heavily to maintain its premium positioning against competitors. This investment appears effective in driving the UK subsidiary’s 36% sales jump, suggesting that new product registrations and regulatory approvals are translating directly into international revenue expansion despite geopolitical headwinds.
The AGM voting patterns further underscore strong institutional alignment with management strategy, as evidenced by the unanimous approval of financial statements and dividends. However, the 3.21% dissent on the director re-appointment suggests minor governance concerns among a subset of public shareholders, contrasting sharply with the complete promoter support.
Historical Stock Returns for 3B BlackBio DX
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +5.40% | +24.91% | +18.68% | +31.38% | +31.38% | +31.38% |
How will the full-year consolidation of Coris BioConcept in FY27 impact the company's overall margin structure and revenue diversification beyond the partial contribution seen in FY26?
Given the geopolitical headwinds in the Middle East, what specific strategies is 3B BlackBio Dx planning to implement to mitigate export risks and sustain growth in that region?
Can the company realistically achieve its 15%-20% growth target for FY27 while simultaneously increasing R&D intensity, and how will this balance affect short-term profitability?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
